Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practiceopen access
- Authors
- Youn, Young Jin; Lee, Jun-Won; Ahn, Sung Gyun; Lee, Seung-Hwan; Yoon, Junghan; Park, Jae Hyoung; Yoo, Sang-Yong; Kang, Woong Chol; Lee, Nam Ho; Kwon, Ki Hwan; Doh, Joon Hyung; Lim, Sang-Wook; Jang, Yang Soo; Jeon, Dong Woon; Heo, Jung Ho; Choi, Woong Gil; Cho, Sungsoo; Lee, Bong-Ki; Jeong, Hyonju; Hong, Bum-Kee; Choi, Hyun-Hee
- Issue Date
- Sep-2023
- Publisher
- 대한내과학회
- Keywords
- Drug-eluting stents; Percutaneous coronary intervention; Prospective studies; Registries
- Citation
- The Korean Journal of Internal Medicine, v.38, no.5, pp 683 - +
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- The Korean Journal of Internal Medicine
- Volume
- 38
- Number
- 5
- Start Page
- 683
- End Page
- +
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/63672
- DOI
- 10.3904/kjim.2023.129
- ISSN
- 1226-3303
2005-6648
- Abstract
- Background/Aims
The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention.
Methods
The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months.
Results
A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%.
Conclusions
In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Cardiology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.